SEARCH

SEARCH BY CITATION

References

  • 1
    Keeffe EB. Occupational risk for hepatitis A: a literature-based analysis. J Clin Gastroenterol 2004; 38: 440-448.
  • 2
    Centers for Disease Control and Prevention. Public health dispatch: multistate outbreak of hepatitis A among young adult concert attendees—United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 844-845.
  • 3
    Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003; 187: 1235-1240.
  • 4
    Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat 2000; 7(Suppl 1): 1-3.
  • 5
    Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004; 38: 705-715.
  • 6
    Centers for Disease Control and Prevention. Foodborne transmission of hepatitis A—Massachusetts, 2001. MMWR Morb Mortal Wkly Rep 2003; 52: 565-567.
  • 7
    Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 1999; 340: 595-602.
  • 8
    Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003; 21: 2224-2233.
  • 9
    O'Donovan D, Cooke RP, Joce R, Eastbury A, Waite J, Stene-Johansen K. An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect 2001; 127: 469-473.
  • 10
    Koff RS. Hepatitis A. Lancet 1998; 351: 1643-1649.
  • 11
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48: 1-37.
  • 12
    Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M. The cost of hepatitis A infections in American adolescents and adults in 1997. HEPATOLOGY 2000; 31: 469-473.
  • 13
    Bianco E, Stroffolini T, Spada E, Szklo A, Marzolini F, Ragni P, et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000: an update. Dig Liver Dis 2003; 35: 404-408.
  • 14
    Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998; 178: 1579-1584.
  • 15
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290.
  • 16
    Wang JY, Lee SD, Tsai YT, Lo KJ, Chiang BN. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci 1986; 31: 109-111.
  • 17
    Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989; 110: 838-839.
  • 18
    Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995; 90: 201-205.
  • 19
    Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999; 93: 745-751.
  • 20
    Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health 2000; 91: 168-170.
  • 21
    Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O'Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002; 49: 524-528.
  • 22
    Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 2003; 21: 2238-2241.
  • 23
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45: 1-30.
  • 24
    World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995; 73: 15-20.
  • 25
    National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. HEPATOLOGY 2002; 36(Suppl): S3-S20.
  • 26
    Department of Veterans Affairs. Hepatitis C Virus (HCV) Testing and Prevention Counseling Guidelines for VA Health Care Practitioners. Available at: http://www.va.gov/hepatitisc/pdf/ce203_testncounslguides. pdf. Accessed January 6, 2005.
  • 27
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147-1171.
  • 28
    American Liver Foundation. Position Statement on Hepatitis A and Vaccination. Available at http://www.liverfoundation.org/db/advocacy/1031. Accessed January 17, 2005.
  • 29
    American College of Gastroenterology. Chronic Liver Disease: A Primer for Vaccinations. Available at: http://www.acg.gi.org/physicianforum/publications/index.html. Accessed December 15, 2004.
  • 30
    Cooksley WG. Consensus statement on the role of hepatitis A vaccination in patients with chronic liver disease. J Viral Hepat 2000; 7(Suppl 1): 29-30.
  • 31
    Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001; 4: 213-227.
  • 32
    Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001; 33: 20-26.
  • 33
    Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004; 19: 715-727.
  • 34
    Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
  • 35
    Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001; 96: 858-863.
    Direct Link:
  • 36
    Duncan M, Hirota WK, Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Am J Gastroenterol 2002; 97: 1792-1795.
    Direct Link:
  • 37
    Sjogren MH. Preventing acute liver disease in patients with chronic liver disease. HEPATOLOGY 1998; 27: 887-888.
  • 38
    Kiefer LA, Honish A, Predy G, Talbot JA. The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000; 162: 207-208.
  • 39
    Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepatol 2005; 12: 101-105.
  • 40
    Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 2002; 47: 384-387.
  • 41
    Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. HEPATOLOGY 1998; 27: 881-886.
  • 42
    Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. HEPATOLOGY 2001; 34: 28-31.
  • 43
    Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427-434.
  • 44
    Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97: 721-728.
    Direct Link:
  • 45
    Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94: 1601-1604.
    Direct Link:
  • 46
    Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72: 272-276.
  • 47
    Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997; 52: 215-218.
  • 48
    Nothdurft HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002; 20: 1157-1162.
  • 49
    Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001; 19: 4710-4719.